Early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell therapies
Our data suggest that early administration of IDM may contribute to a rapid resolution of severe or steroid-refractory ICANS after CAR-T cell therapies, which may create opportunities for subsequent treatments in these patients. Larger sample and multicenter clinical trials are warranted to further validate these findings.
Authors
- Mingfeng Zhao (ORCID: https://orcid.org/0009-0006-2503-6677)
- Xue Bai (ORCID: https://orcid.org/0000-0002-7283-3189)
- Hairong Lyu (ORCID: https://orcid.org/0000-0002-0367-8760)
- Haibo Zhu (ORCID: https://orcid.org/0000-0002-0515-9833)
- Zhao Wang (ORCID: https://orcid.org/0000-0001-6095-7232)
- Xiaoyuan He
- Xia Xiao (ORCID: https://orcid.org/0000-0001-6168-2963)
- Juanxia Meng
- Yedi Pu
Institutions
- Tianjin First Center Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.3389/fimmu.2025.1716317
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China